Search Results - "Sharkhawy, Marlies"

Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial by Gruppo, Ralph, López‐Fernández, Maria‐Fernanda, Wynn, Tung T., Engl, Werner, Sharkhawy, Marlies, Tangada, Srilatha

“…Introduction Rurioctocog alfa pegol (BAX 855, TAK‐660) is a PEGylated, full‐length, recombinant factor VIII (rFVIII) with extended half‐life developed from…”
Get full text

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding by Mullins, Eric S., Knoll, Christine M., Dunn, Amy L., Engl, Werner, Sharkhawy, Marlies, Abbuehl, Brigitt E.

“…Introduction: Hemophilia A (HA) is an X linked recessive bleeding disorder characterized by frequent bleeding predominantly in joints. To avoid the sequelae of…”
Get full text

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life by Dunn, Amy L., Thompson, Alexis A., Engl, Werner, Sharkhawy, Marlies, Abbuehl, Brigitt E.

“…Introduction: Patients with hemophilia A are at risk for acute bleeding which may affect muscles and other soft tissues but characteristically involves joints…”
Get full text

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency by Wasserman, Richard L., Melamed, Isaac, Stein, Mark R., Engl, Werner, Sharkhawy, Marlies, Leibl, Heinz, Puck, Jennifer, Rubinstein, Arye, Kobrynski, Lisa, Gupta, Sudhir, Grant, Andrew J., Ratnayake, Anoshie, Richmond, Wendell G., Church, Joseph, Yel, Leman, Gelmont, David

“…Purpose Treatment of primary immunodeficiency diseases (PIDD) with subcutaneous (SC) infusions of IgG preceded by injection of recombinant human hyaluronidase…”
Get full text

Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability by Wasserman, Richard L, Melamed, Isaac, Kobrynski, Lisa, Puck, Jennifer, Gupta, Sudhir, Doralt, Jennifer, Sharkhawy, Marlies, Engl, Werner, Leibl, Heinz, Gelmont, David, Yel, Leman

“…To assess the long-term efficacy, safety and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG;…”
Get full text

Hemostatic efficacy of latest-generation fibrin sealant after hepatic resection: a randomized controlled clinical study by Bektas, Hüseyin, Nadalin, Silvio, Szabo, Ildiko, Ploder, Bettina, Sharkhawy, Marlies, Schmidt, Jan

“…Purpose This randomized, controlled, single-blinded multicenter study evaluated the efficacy of latest-generation fibrin sealant containing synthetic aprotinin…”
Get full text

Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease by Wasserman, Richard L., Melamed, Isaac, Kobrynski, Lisa, Strausbaugh, Steven D., Stein, Mark R., Sharkhawy, Marlies, Engl, Werner, Leibl, Heinz, Sobolevsky, Luba, Gelmont, David, Schiff, Richard I., Grossman, William J.

“…A multi-center, prospective, open-label study was conducted in primary immunodeficiency disease patients to determine the tolerability and pharmacokinetics of…”
Get full text

Efficacy and Safety of a New Intravenous Immunoglobulin in Adult Subjects with Chronic Idiopathic Thrombocytopenic Purpura by Leibl, Heinz, Varga, Gyula, Volkova, Zuzana, Gasztonyi, Zoltan, Hlusi, Antonin, Mayer, Jiri, Chojnowski, Krzysztof, Wolf, Hans-Heinrich, Sharkhawy, Marlies, Pavlova, Borislava G., Birthistle, Karl, Engl, Werner, Walter, Simone, Ehrlich, Hartmut J.

“…Idiopathic thrombocytopenic purpura (ITP) is a common clinical disorder of immune regulation leading to phagocytic destruction of platelets. Intravenous…”
Get full text